

ATTORNEY'S DOCKET NUMBER: 0157755-0257 (BHC 031001 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Munnes, et al.

Examiner:

Not yet assigned

Serial No:

10/561,485

Group Art Unit:

Not yet assigned

Filing Date:

December 16, 2005

Title:

Methods and Kits for Investigating Cancer

Mail Stop: Amendments Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Statement under 37 C.F.R. §§ 1.56, 1.97, and 1.98 (6 pages);
- 2. Form PTO-1449 (8 pages);
- 3. Cited Art (127 references); and
- 4. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

Cameron M. Luitjens, Ph.D. Registration Number: 58,674

PATENT GROUP CHOATE, HALL & STEWART, LLP Two International Place Boston, MA 02110 Tel (617) 248-5000 Fax (617) 248-4000

Dated: July /, 2006

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

July 5, 2006

Date

Signature

Vincent Montalbano

Typed or Printed Name of person signing certificate



ATTORNEY'S DOCKET NUMBER: 0157755-0257 (BHC 031001 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Munnes, et al.

Examiner:

Not yet assigned

Serial No:

10/561,485

Group Art Unit:

Not yet assigned

Filing Date:

December 16, 2005

Title:

Methods and Kits for Investigating Cancer

Mail Stop: Amendments Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Pursuant to the duty of disclosure under 37 C.F.R §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

An original Information Disclosure Statement; or [X]

A supplemental Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria,

VA 22313-1450. July 🗸

Date

Signature

Vincent Montalbano

Name of Person Signing

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

[X]	Pursua	ant to 37	CFR § 1.97(b); no fee or certification is required:
	[]	Withir	three months of the filing date of a national application other than
		a conti	inued prosecution application under § 1.53(d);
	[]	Withir	three months of the date of entry of the national stage as set forth
		in § 1.	491 in an international application;
	[X]	Before	e the mailing of a first Office action on the merits; or
	[]	Before	e the mailing of a first Office action after the filing of a request for
		contin	ued examination under § 1.114.
[]	Pursua	ant to 37	7 CFR § 1.97(c) after the dates listed above but before the mailing
	date o	f any of	a final action under § 1.113, a notice of allowance under § 1.311, or
	an act	ion that	otherwise closes prosecution in the application; Applicant hereby
	either	:	
	[]	Certif	ies that either:
		[]	each item of information contained in the information disclosure
			statement was first cited in any communication from a foreign
			patent office in a counterpart foreign application not more than
			three months prior to the filing of the information disclosure
			statement; or
		[]	That no item of information contained in the information
			disclosure statement was cited in a communication from a foreign
			patent office in a counterpart foreign application, and, to the
			knowledge of the person signing the certification after making
			reasonable inquiry, no item of information contained in the Page 2 of 6

information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; or

	[]	Includ	es herewith the fee set forth in § 1.17(p),
[]	Pursua	int to 37	7 CFR § 1.97(d), after the mailing date of any final action under
	§ 1.11	3, a not	ice of allowance under § 1.311, or an action that otherwise closes
	prosec	ution in	the application; Applicant hereby both:
	[]	Certifi	es that either:
		[]	each item of information contained in the information disclosure
			statement was first cited in any communication from a foreign
			patent office in a counterpart foreign application not more than
			three months prior to the filing of the information disclosure
			statement; or
		[]	That no item of information contained in the information
			disclosure statement was cited in a communication from a foreign
			patent office in a counterpart foreign application, and, to the
			knowledge of the person signing the certification after making
			reasonable inquiry, no item of information contained in the
			information disclosure statement was known to any individual
			designated in § 1.56(c) more than three months prior to the filing
			of the information disclosure statement; and
	[]	Includ	les herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- [X] A copy of each cited reference not indicated with an asterisk is included;
- [X] A copy of each of the references cited on the attached form PTO-1449 (modified) is enclosed, except for U.S. patents and U.S. patent application publications for which the submission requirement has been waived by the PTO in the Official Gazette Notice of August 5, 2003, for applications filed after June 30, 2003;
- [] Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

[] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the aboveidentified application:

Applicant certifies that the Information Disclosure Statement either:

- [X] Does not contain non-English language citations;
- [] Includes one or more translations of a non-English citation; or

[] Does contain non-English language citations, of which the following is a concise explanation:

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b).

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 USC § 102.

It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
- 3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Dated: July /, 2006

Cameron M. Luitjens, Ph.D. Registration Number: 58,674

PATENT GROUP CHOATE, HALL & STEWART, LLP Two International Place Boston, Massachusetts 02110 Tel (617) 248-5000 Fax (617) 248-4000

Form PTO-14	49 OTPE U.S. De	epartment of	Atty. Docket:	In re Applie	cation No.
(Comme	erce	0157755-0257	10/561,485	
(REV. 8-83)	JUL 0 7 2006 'Patent a	and Trademark Office			
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicant: Munnes, et al.		
			Filing Date:	Group:	
(036 36	verus sneets if necessus	<i>)</i>	December 16, 2005		
U.S. PATENT	DOCUMENTS				
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	4,683,195	Mullis, et al.	July 28, 1987	435	6
	4,683,202	Mullis	July 28, 1987	435	91
	4,843,155	Chomczynski	June 27, 1989	536	27
	5,223,409	Ladner, et al.	June 29, 1993	435	69.7
	5,262,311	Pardee, et al.	November 16, 1993	435	91.2
	5,283,317	Saifer, et al.	February 1, 1994	528	405
	5,498,531	Jarrell	March 12, 1996	435	91.31
	5,556,752	Lockhart, et al.	September 17, 1996	435	6
	5,565,332	Hoogenboom, et al.	October 15, 1996	435	69.1
-	5,578,832	Trulson, et al.	November 26, 1996	250	458.1
	5,593,839	Hubbell, et al.	January 14, 1997	435	6
	5,599,695	Pease, et al.	February 4, 1997	435	91.1
	5,631,734	Stern, et al.	May 20, 1997	356	317
	5,641,673	Haseloff, et al.	June 24, 1997	435	325
	5,705,151	Dow, et al.	January 6, 1998	424	93.21
	5,714,331	Buchardt, et al.	February 3, 1998	435	6
	5,976,813	Beutel, et al.	November 2, 1999	435	7.1
	6,203,987	Friend, et al.	March 20, 2001	435	6
U.S. PATENT	APPLICATIONS				
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:
	2003-143539	Bertucci, et al.	July 31, 2003		
FOREIGN PA	ATENT DOCUMENT		<u> </u>		
Examiner's	Document No.	Country	Date	Translation	
Initials				Yes	No
	WO 1993/03151	WO	February 18, 1993		
	WO 1994/10300	WO	May 11, 1994		
	WO 1994/13804	WO	June 23, 1994		
	WO 1995/22058	WO	August 17, 1995		

Form PTO-1449 (REV. 8-83)	· Comme	epartment of erce and Trademark Office	Atty. Docket: 0157755-0257	In re Application No. 10/561,485
REV. 0-03)			Applicant: Munnes, et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Filing Date:	Group:
		· ·	December 16, 2005	
	WO 1997/02357	WO	January 23, 1997	
	WO 1997/14028	WO	April 17, 1997	
	WO 1997/27317	WO	July 31, 1997	
	WO 1997/29212	WO	August 14, 1997	
	WO 1999/12826	WO	March 18, 1999	
	EP 0 321 201	Europe	December 14, 1988	
	EP 0 721 016	Europe	October 20, 1995	
	EP 0 728 520	Europe	February 8, 1996	
	EP 0 799 897	Europe	April 3, 1997	
	EP 0 785 280	Europe	November 28, 1996	
	GB 2188638			
OTHER DOCU	MENTS			
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)			
		Detection Of Point Mut Res. 23(4): 675-682, 199		Ligase Chain Reaction (Gap
				"Trends Biotechnol., 10:
	Agrawal and Goodchild, "Oligodeoxynucleoside Methylphosponates: Synthesis And Enzym Degradation," <i>Tetrahedron Letters</i> , 28 : 3539-3542, 1987.			
	Altschul, et al., "O 603-616, 1986.	ptimal Sequence Align	ment Using Affine Gap	Costs," Bull. Math. Bio., 48:
	Bartel, et al., "Elir BioTechniques, 14		ves That Arise In Using	The Two-Hybrid System,"
	Bitter, et al., "Exp. 544, 1987.	ression And Secretion V	Vectors For Yeast," Meth	hods in Enzymol., 153: 516-
		thy, "A General Metho Sci. USA, 48 : 1390-139		NA Complement To DNA,
	Bonner, et al., "Reduction In The Rate Of DNA Reassociation By Sequence Divergence," J. Mol. Biol., 81: 123-135, 1973.			
	Broglie, et al., "Light-Regulated Expression Of A Pea Ribulose-1,5-Bisophosphate Carboxylase Small Subunit Gene In Transformed Plant Cells," Science, 224: 838-843, 1984.			
	Brown, "A Brief H	History Of Oligonucleot	ide Synthesis," Meth. M	ol. Biol., 20: 1-17, 1993.
		al On Support Vector M very, 2(2): 121-167, 199		cognition," Data Mining and

Form PTO-1449 (REV. 8-83)	9 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0157755-0257	In re Application No. 10/561,485		
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Munnes, Filing Date: December 16, 2005	et al. Group:		
-		Burton, "Antibody Redesign By Chain Shuffling From Random Combinatorial mmunoglobulin Libraries," <i>Proc. Natl. Acad. Sci.</i> , 88 : 11120-11123, 1991.			
	Carell, et al., "A Novel Procedure For The Molecules," Angew. Chem. Int. Ed. Engl.,		Containing Small Organic		
	Caruthers, et al., "New Chemical Methods Symp. Ser., 7: 215-223, 1980.	For Synthesizing Poly	nucleotides," Nucl. Acids Res.		
	Cech, "Self-Splicing Of Group I Introns,"	Ann. Rev. Biochem., 5 9	9: 543-568, 1990.		
	Cech, "The Chemistry Of Self-Splicing R1 1987.	NA And RNA Enzymes	s," Science, 236 : 1532-1539,		
	Cho, et al., "An Unnatural Biopolymer," Science, 261: 1303-1305, 1993.				
	Clahsen, et al., "p53 Protein Accumulation And Response To Adjuvant Chemotherapy In Premenopausal Women With Node-Negative Early Breast Cancer," J. of Clinical Oncology, 16(2): 470-479, 1998.				
	Cohen, et al., "A First-Generation Physical Map Of The Human Genome," Nature, 366: 698-701, 1993.				
	Colbere-Garapin, et al., "A New Dominant Hybrid Selective Marker For Higher Eukaryotic Cells," J Mol Biol., 150(1): 1-14, 1981.				
	Cole, et al., "Human Monoclonal Antibodies," Mol Cell Biochem., 62(2): 109-20, 1984.				
	Coloma and Morrison, "Design And Production Of Novel Tetravalent Bispecific Antibodies," <i>Nat. Biotechnol</i> , 15 : 159-163, 1997.				
	Copeland and Jenkins, "Development And Applications Of A Molecular Genetic Linkage Map Of The Mouse Genome," <i>Trends in Genetics</i> , 7: 113-118, 1991.				
	Coruzzi, et al., "Tissue-Specific And Light-Regulated Expression Of A Pea Nuclear Gene Encoding The Small Subunit Of Ribulose-1,5-Bisphosphate Carboxylase," EMBO J., 3: 1671-1680, 1984.				
	Cote, et al., "Generation Of Human Monoclonal Antibodies Reactive With Cellular Antigens," Proc. Natl. Acad. Sci., 80: 2026-2030, 1983.				
	Couture and Stinchcomb, "Anti-Gene Therapy: The Use Of Ribozymes To Inhibit Gene Function," <i>Trends in Genetics</i> , 12: 510-545, 1996.				
	Cronin, et al., "Cystic Fibrosis Mutation D Probe Arrays," Human Mutation, 7: 244-2		tion To Light-Generated DNA		
	Cull, et al., "Screening For Receptor Ligar C Terminus Of The lac Repressor," Proc.				
	Cwirla, et al., "Peptides On Phage: A Vast Natl. Acad. Sci., 87: 6378-6382, 1990.	Library Of Peptides Fo	or Identifying Ligands," Proc.		
	Devlin, "Random Peptide Libraries: A Sou Science, 249: 404-406, 1990.	arce Of Specific Protein	n Binding Molecules,"		

FORM F 10-1449	· Commerce	0157755-0257	10/561,485		
(REV. 8-83)	Patent and Trademark Office		ĺ		
DEODMATIO	N DICCLOSIDE STATEMENT	Applicant: Munnes, e	t al.		
(Use several sheets if necessary)		Filing Date: December 16, 2005	Group:		
	DeWitt, et al., "'Diversomers': An Approx Diversity," Proc. Natl. Acad. Sci. USA, 90		noligomeric Chemical		
	Engelhard, et al., "The Insect Tracheal Sys Autographa californica M Nuclear Polyhe 1994.				
	Erb, et al., "Recursive Deconvolution Of C Sci. USA, 91: 11422-11426, 1994.	Combinatorial Chemical	Libraries," Proc. Natl. Acad.		
	Felici, "Selection Of Antibody Ligands Fro A Multivalent Exposition Vector," J. Mol.				
	Findeis, et al., "Targeted Delivery Of DNA Biotechnol., 11: 202-205, 1993.	A For Gene Therapy Via	Receptors," Trends in		
	Fodor, "Multiplexed Biochemical Assays With Biological Chips," Nature, 364: 555-556, 1993.				
	Foekens, et al., "Prognostic Significance Cancer," J. of Clinical Oncology, 16(3): 10	te Of Cathepsins B and L In Primary Human Breast 1013-1021, 1998. Inatorial Technologies To Drug Discovery. 1. I Libraries," J. Med. Chem., 37: 1233-1251, 1994.			
	Gasparini, et al., "Expression Of bcl-2 Pro Operable Node-Positive Breast Cancer," C				
		plification Of Nucleic Acids By A Multienzyme lication," <i>Proc. Natl. Acad. Sci. USA</i> , 87: 1874-1878,			
	Hartman and Mulligan, "Two Dominant-ad In Mammalian Cells," <i>Proc. Natl. Acad. Selection</i> 10 (2016)	cting Selectable Marker ci., 85 : 8047-8051, 1988	s For Gene Transfer Studies 3.		
	Haseloff, et al., "Simple RNA Enzymes W Activities," Nature, 334: 585-591, 1988.	ith New And Highly Sp	pecific Endoribonuclease		
	Hedrick, et al., "Isolation Of cDNA Clone Proteins," Nature, 308: 149-153, 1984.	s Encoding T Cell-Spec	ific Membrane-Associated		
	Henikoff and Henikoff, "Amino Acid Subsacad. Sci. USA, 89: 10915-10919, 1992.	abstitution Matrices From Protein Blocks," Proc. Natl.			
1 ' '		tides On Cellulose. Part II: Design And Synthetic leoxynucleotides Coding For Gastric Inhibitory mp. Ser., 7: 225-232, 1980.			
	Houghten, et al., "The Use Of Synthetic Pe Of Bioactive Peptides," BioTechniques, 13		braries For The Identification		
	Iwabuchi, et al., "Use Of The Two-Hybrid Oligomerization," Oncogene, 8: 1693-1696		e Domain Of p53 Involved In		
	Jayawickreme, et al., "Creation And Funct	_	fulti-Use Peptide Library,"		

Form PTO-1449 (REV. 8-83)	U.S. Department ofCommercePatent and Trademark Office	Atty. Docket: 0157755-0257	In re Application No. 10/561,485	
(RE v. 0-03)	ratem and trademark office	Applicant: Munnes, et al.		
	DISCLOSURE STATEMENT al sheets if necessary)	Filing Date: December 16, 2005	Group:	
	Kohler, et al., "Continuous Cultures Of Fu Specificity," Nature, 256: 495-497, 1975.	ised Cells Secreting Ant	ibody Of Predefined	
	Kopp, et al., "Predictive Relevance Of Sol To Second Line Hormone- Or Chemothera Anticancer Research, 21: 2995-3000, 2001	apy In Patients With Me		
	Kozbor, et al., "Specific Immunoglobulin Ascites Growth Of Human Hybridomas,".			
	Kroll, et al., "A Multifunctional Prokaryot Affinity Purification, And Selective Detec			
	Kwoh, et al., "Transcription-based Amplif Immunodeficiency Virus Type 1 With A E Natl. Acad. Sci. USA, 86: 1173-1177, 1989	Bead-Based Sandwich H		
	Lagerstrom, et al., "Capture PCR: Efficient Amplification Of DNA Fragments Adjacent To A Known Sequence In Human And YAC DNA," PCR Methods Applic., 1: 111-119, 1991.			
II.	Lam, "Application Of Combinatorial Libra Discovery," Anticancer Drug Des., 12: 14		Research And Drug	
1	Lam, "A New Type Of Synthetic Peptide Library For Identifying Ligand-Binding Activity," Nature, 354: 82-84, 1991.			
	Landegran, et al., "A Ligase-mediated Gene Detection Technique," Science, 241: 1077-1080, 1988.			
	Lee, et al., "Leukotriene E4-induced Airway Hyperresponsiveness Of Guinea Pig Tracheal Smooth Muscle To Histamine And Evidence For Three Separate Sulfidopeptide Leukotriene Receptors," <i>Proc. Natl. Acad. Sci. USA</i> , 81: 4922-4925, 1984.			
	Lizardi, et al., "Exponential Amplification Of Recombinant-RNA Hybridization Probes," Bio/ Technology, 6: 1197-1202, 1988.			
	Logan and Shenk, "Adenovirus Tripartite Leader Sequence Enhances Translation Of mRNAs Late After Infection," <i>Proc. Natl. Acad. Sci.</i> , 81 : 3655-3659, 1984.			
	Lowy, et al., "Isolation Of Transforming I 817-823, 1980.	ONA: Cloning The Ham	ster Aprt Gene," Cell, 22:	
	Maddox, et al., "Elevated Serum Levels Ir Immunochemically Similar To Eosinophil 1211-1226, 1983.			
	Madura, et al., "N-Recognin/Ubc2 Interac 268 : 12046-12054, 1993.	tions In The N-end Rule	e Pathway," J. Biol. Chem.,	
	Mallender and Voss, "Construction, Exprechain Antibody," J. Biol. Chem., 269: 199		A Bivalent Bispecific Single-	
	McConnell, et al., "The Cytosensor Micro Technology," Science, 257: 1906-1912, 19		Applications Of Silicon	

Form PTO-1449 (REV. 8-83)	U.S. Department ofCommercePatent and Trademark Office	Atty. Docket: 0157755-0257	In re Application No. 10/561,485		
INFORMATION	DISCLOSURE STATEMENT ral sheets if necessary)	Applicant: Munnes, of Filing Date: December 16, 2005	et al. Group:		
	Merrifield, "Solid Phase Peptide Synthesis Soc., 85 : 2149-2154, 1963.	Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis Of A Tetrapeptide," J. Am. Chem. Soc., 85: 2149-2154, 1963.			
	Morrison, et al., "Chimeric Human Antibo With Human Constant Region Domains,"				
	Munster, et al., "Predictive Factor For The Breast Cancer," Breast Cancer Res., 3(6):		t Therapy With Emphasis In		
	Muss, et al., "c-erB-2 Expression And Res Positive Early Breast Cancer," New England				
	Nakazawa, et al., "UV And Skin Cancer: S Biologically Relevant Exposure Measurem				
	Needleman and Wunsch, "A General Method Applicable To The Search For Similarities In Th Amino Acid Sequence Of Two Proteins," J. Mol. Biol., 48: 444-453, 1970.				
	Neuberger, et al., "Recombinant Antibodies Possessing Novel Effector Functions," Nature, 312: 604-608, 1984.				
	Nicholls, et al., "An Improved Method For Generating Single-Chain Antibodies From Hybridomas," J. Immunol. Meth., 165: 81-91, 1993.				
	Orlandi, et al., "Cloning Immunoglobulin Variable Domains For Expression By The Polymerase Chain Reaction," Proc. Natl. Acad. Sci., 86: 3833-3837, 1989.				
	Pearson, et al., "Rapid And Sensitive Sequence Comparison With FASTP And FASTA," Meth. Enzymol., 183: 63-98, 1990.				
	Pearson and Lipman, "Improved Tools For Biological Sequence Comparison," <i>Proc. Natl. Acad. Sci. USA</i> , 85 : 2444-2448, 1988.				
	Perez, "Current Management of Metastatic Breast Cancer," Semin. Oncol., 26(suppl.12): 1-10, 1999.				
	Porath, et al., "Immobilized Metal Ion Affinity Chromatography," Prot. Exp. Purif. 3: 263-281, 1992.				
	Premzl, et al., "Intracellular And Extracellular Cathepsin B Facilitate Invasion Of MCF-10A neoT Cells Through Reconstituted Extracellular Matrix In Vitro," Experimental Cell Research, 283(2): 206-214, 2003.				
	Rhodes, et al., "Transformation Of Maize By Electroporation Of Embryos," Methods Mol. Biol., 55: 121-131, 1995.				
	Roberge, et al., "A Strategy For A Convergent Synthesis Of N-Linked Glycopeptides On A Solid Support," Science, 269: 202-207, 1995.				
	Saleh, et al., "Effects Of Combined In Viv Carcinoma In Wistar Rats Using Vitamin I Placenta," J. of Experimental Ther. & Onc	E And Cysteine Peptida	ase Inhibitors From Human		
	Salmon, et al., "High-volume Cellular Screechemical Libraries: A New Methodology,	_	_		

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0157755-0257	In re Application No. 10/561,485	
(REV. 8-83)	Fatent and Trademark Office	Applicant: Munnes, et al.		
30 15 30 20 27 27 27 27 2	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Group:	
	Sarkar, et al., "Restriction-site PCR: A Dir Adjacent To A Known Locus By Using Ur 1993.	rect Method Of Unknowniversal Primers," PCR	n Sequence Retrieval Methods Applic., 2: 318-322,	
	Scharf, et al., "Heat Stress Promoters And 20 : 125-162, 1994.	Transcription Factors,"	Results Probl. Cell Differ.,	
	Scorilas, et al., "Determination Of Catheps Information For Ovarian Cancer Patients,"	in B Expression May O Biological Chem., 383:	ffer Additional Prognostic 1297-1303, 2002.	
	Scott and Smith, "Searching For Peptide L. 390, 1990.	igands With An Epitope	Library," Science, 249: 386-	
	Sellers, "On The Theory And Computation 26: 787-793, 1974.	of Evolutionary Distar	nces," SIAM J. Appl. Math.,	
	Sjolander and Urbaniczky, "Integrated Flui Analysis," <i>Anal. Chem.</i> , 63 : 2338-2345, 19		Biomolecular Interaction	
	Sonveaux, "Protecting Groups In Oligonuc	eotide Synthesis," Meth. Mol. Biol. 26: 1-71, 1994.		
	Sorlie, et al., "Gene Expression Patterns O With Clinical Implications," Proc Natl Acc			
	Szabo, et al., "Surface Plasmon Resonance (BIA)," Curr. Opin. Struct. Biol., 5: 699-70		ecular Interaction Analysis	
	Takamatsu, "Expression Of Bacterial Chlo Plants Mediated By TMV-RNA," EMBO	oramphenicol Acetyltransferase Gene In Tobacco J., 6: 307-311, 1987.		
	Takeda, et al., "Construction Of Chimaeric Mouse Variable And Human Constant Reg			
	Tedder, et al., "Isolation And Structure Of Antigen Of Human B Lymphocytes," Proc			
	Thirion, et al., "Mono- And Bispecific Sin Eur. J. Cancer Prev., 5: 507-511, 1996.	gle-chain Antibody Frag	gments For Cancer Therapy,"	
	Triglia, et al., "A Procedure For In Vitro A The Boundaries Of Known Sequences," N			
	Uhlmann, et al., "Antisense Oligonucleotic 543-584, 1990.	des: A New Therapeutic	Principle," Chem. Rev., 90:	
	Van Heeke and Schuster, "Expression Of I J. Biol. Chem., 264: 5503-5509, 1989.	Human Asparagine Synt	hetase In Escherichia coli,"	
	van't Veer, et al., "Gene Expression Profil Nature, 415(6871): 530-6, 2002.	ing Predicts Clinical Ou	tcome Of Breast Cancer,"	
	Verhaar, et al., "A Single Chain Fv Derive Tumour Targeting Advantages Over One I 497-501, 1995.		-	

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0157755-0257	In re Application No. 10/561,485	
		Applicant: Munnes, et	al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: December 16, 2005	Group:	
	Wigler, et al., "Transfer Of Purified Herper Cells," Cell, 11: 223-232, 1977.	s Virus Thymidine Kinas	se Gene To Cultured Mouse	
	Wigler, et al., "Transformation Of Mamma Gene," Proc. Natl. Acad. Sci., 77: 3567-35		olifiable Dominant-acting	
	Winter, et al., "Man-made Antibodies," Na	nture, 349 : 293-299, 199	1.	
	Winter and Sinibaldi, "The Expression Of Plant Development," Results Probl. Cell D	Heat Shock Protein And Cognate Genes During Differ., 17: 85-105, 1991.		
	Wu and Wu, "Receptor-mediated Gene De 14621-14624, 1988.	livery And Expression I	n Vivo," J. Biol. Chem., 263:	
	Wu, et al., "Receptor-mediated Gene Deliving 1991.	ivery in Vivo," J. Biol. Chem., 266: 14338-14342, Into A Ligand-based DNA Carrier System Results Inty And Enhances Targeted Gene Expression," J. Biol.		
	Wu, et al., "Incorporation Of Adenovirus I Retention Of Original Receptor Specificity Chem., 269: 11542-11546, 1994.			
	Yan, et al., "Cathepsin B And Human Tumor Progression," Biological Chemistry, 379(2): 113-123, 1998.			
Zenke, et al., "Receptor-mediated Endocytosis Of Transferrin-Polycation Conjugation Efficient Way To Introduce DNA Into Hematoppietic Cells," <i>Proc. Natl. Acad. Sci.</i> 3655-3659, 1990.				
	Zervos, et al., "Mxi1, A Protein That Specifically Interacts With Max To Bind Myc-M. Recognition Sites," Cell, 72: 223-232, 1993.		lax To Bind Myc-Max	
	Zuckermann, et al., "Discovery Of Nanom Coupled Receptors From A Diverse N-(Su 37: 2678-2685, 1994.	olar Ligands For 7-Tran bstituted)glycine Peptoid	smembrane G-Protein-d Library," <i>J. Med. Chem.</i> ,	
EXAMINER	DATE CONSIDERED			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.